How to effectively plan the number and type of monitoring visits in a clinical trial?

How to effectively plan the number and type of monitoring visits in a clinical trial?

Planning monitoring visits is one of the key operational components of a clinical trial, directly impacting data quality, patient safety, project costs, and timely delivery. An effective monitoring plan today goes beyond simply deciding how many visits to conduct and how often. It requires a deliberate selection of visit types, intensity, and timing, based on the study’s specific risk profile.

The foundation of a modern approach is risk-based monitoring (RBM), aligned with the Quality by Design philosophy. This means that the number and type of monitoring visits should result from a risk assessment performed already at the study planning stage. Critical factors include protocol complexity, site experience, key data collection points, patient safety considerations, recruitment pace, and prior experience with similar projects.

In practice, this involves moving away from a uniform model of frequent on-site visits toward a hybrid model combining remote monitoring, central monitoring, and targeted on-site visits. Remote and central monitoring enable ongoing identification of deviations, trends, and potential non-compliance, while on-site visits are focused on critical milestones such as site initiation, first patient visits, escalation of quality issues, or study close-out.

Proper timing and distribution of visits are equally important. Excessive monitoring at the beginning of a study may generate unnecessary costs, whereas insufficient oversight during early recruitment increases the risk of systemic errors that are difficult to correct later. A well-designed monitoring plan is flexible and allows for adjustment of visit frequency in response to real operational data.

Clear roles and responsibilities also play a crucial role. Monitors and the Project Manager should operate under a unified monitoring plan that clearly defines the objectives of each visit, the scope of verification, and escalation criteria. Monitoring should not be treated as retrospective control, but as a proactive study management tool.

From a business perspective, effectively planned monitoring visits translate into tangible time and budget savings, reduced risk of major non-compliance, and greater project predictability. Increasingly, sponsors view monitoring not as a cost, but as an investment in data quality and study stability. Properly planning the number and type of visits makes it possible to achieve these goals without overburdening teams and sites.

If you would like to design a monitoring strategy tailored to the real risks of your study while optimizing project timelines and costs, contact us — we will help you implement solutions that genuinely support quality and on-time delivery.

Other questions: Design and implementation of the study

See also

What Is Interim Analysis (IA) and What Challenges Does It Involve? What Is Interim Analysis (IA) and What Challenges Does It Involve?
Interim Analysis (IA) is an analysis of data conducted during an ongoing clinical trial, before its official completion and database lock. Its purpose is to ...
What Is the Difference Between a Submission and a Notification in a Clinical Trial? What Is the Difference Between a Submission and a Notification in a Clinical Trial?
In clinical research, the terms submission and notification are frequently used. Although both refer to providing documents or information to the relevant au...
What Types of Research Sites Participate in Clinical Trials? What Types of Research Sites Participate in Clinical Trials?
Clinical and observational studies can be conducted in a variety of healthcare settings. Contrary to common belief, a research site does not have to be a lar...
Copyright© 2023 Biostat